Patent application number | Description | Published |
20100266637 | METHOD OF PREVENTING EARLY LAWSONIA INTRACELLULARIS INFECTIONS - The present invention relates inter alia to the use of a combination of a vaccine against | 10-21-2010 |
20110052629 | METHODS OF REDUCING CONCOMITANT INFECTIONS IN PIGS WITH A PCV2 ANTIGEN - The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers to a method for improving the resistance of pigs against concomitant infections with pathogens other than PCV2, comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. | 03-03-2011 |
20130115236 | PROPHYLAXIS AND TREATMENT OF PRDC - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs. | 05-09-2013 |
20130156811 | METHOD OF PREVENTING EARLY LAWSONIA INTRACELLULARIS INFECTIONS - The present invention relates inter alia to the use of a combination of a vaccine against | 06-20-2013 |
20130183337 | KIT FOR THE PREPARATION OF A VACCINATING AGENT - A kit, a method of using it and a process for preparing a vaccine for immunization against the disease Porcine Circovirus Disease and/or Enzootic Pneumonia in pigs are proposed, in which a first container is only partly filled with a first vaccine and a second container is filled with a second vaccine, the second vaccine being transferred into the first container through an adapter device, when a closure device is penetrated for the first and/or only time, and the vaccinating agent is prepared therein, thus making the operation simple, less error-prone and more hygienic, while reducing the materials required. The adapter device has a pair of oppositely facing piercing elements formed of one of needles, hollow, spikes, wedges with at least one through passage extending through both piercing elements, each of the containers being pierced by a respective one of the piercing elements creating a fluid connection between the containers. | 07-18-2013 |
20130230558 | ONE DOSE VACCINATION AGAINST MYCOPLASMA INFECTIONS OF PIGS - The present invention provides a one phase, aqueous vaccine composition for immunizing an animal against infection by | 09-05-2013 |
20130273099 | PREVENTION AND TREATMENT OF SUB-CLINICAL PCVD - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment of sub-clinical PCV2 infection in animals, preferably in pigs. | 10-17-2013 |
20130302370 | REDUCTION OF CONCOMITANT INFECTIONS IN PIGS BY THE USE OF PCV2 ANTIGEN - The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers to a method for improving the resistance of pigs against concomitant infections with pathogens other than PCV2, comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. | 11-14-2013 |
20140370058 | ONE DOSE VACCINATION AGAINST MYCOPLASMA INFECTIONS OF PIGS - The present invention provides a one phase, aqueous vaccine composition for immunizing an animal against infection by | 12-18-2014 |
20140377298 | TREATMENT OF PIGS WITH PCV2 ANTIGEN - The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets. | 12-25-2014 |